Screener
Spyre Therapeutics, Inc. SYRE Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Payment of deferred offering costs in connection with shelf registration | (171) | (93) |
| Proceeds from employee stock option exercises and employee stock plan purchases | 2,676 | 218 |
| Net cash provided by financing activities | 12,255 | 125 |
| NET DECREASE IN CASH AND CASH EQUIVALENTS | 11,464 | (40,930) |
| CASH AND CASH EQUIVALENTS | ||
| Beginning of period | 85,721 | 89,423 |
| End of period | $97,185 | $48,493 |
| Supplemental Disclosure of Non-Cash Financing Information: |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Spyre Therapeutics, Inc.'s net change in cash?
- Spyre Therapeutics, Inc. (SYRE) reported net change in cash of $11.46M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s net change in cash changed year-over-year?
- Spyre Therapeutics, Inc.'s net change in cash increased by 128.0% year-over-year, from -$40.93M to $11.46M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Spyre Therapeutics, Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude